Catalyst Wire Dossier Catalyst Wire Dossier

Autologous tumor-infiltrating lymphocytes (TIL) therapy

tumor-infiltrating lymphocytes
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Autologous tumor-infiltrating lymphocytes (TIL) therapy, covering 2014-11-24 to 2026-02-24. Get the full timeline:

Most recent: Clinical Trial Update: Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients [Phase 1]

See pricing